Sage Journals: Discover world-class research

Abstract

Research on fullerenes occupies a unique position in the scientific arena. Synthesis and characterisation of this nanomaterial blur the line between materials science and chemistry; careful tuning of the processing methods gives birth to a whole family of molecules and their functionalised derivatives, whose unusual properties at this nanoscopic scale can be exploited in cutting-edge technological applications. This review focuses on the functionalisation of fullerenes for use in medical applications. The first half gives an introduction to the fullerenes themselves and how their fundamental properties lead to a very rich chemistry, enabling both exohedral (external) and endohedral (internal) functionalisations of the cage. Emphasis is placed on the need for safe and reproducible synthesis routes if fullerenes are ever going to make it to the pharmaceutical market. In line with this, a selection of exohedral functionalisation protocols receives particular attention. Coverage of endohedral fullerene synthesis routes is limited to the endohedral metallofullerenes. In the second half, myriad applications of fullerenes in biomedical contexts are introduced and certain synthesis routes are critically evaluated. Discussion of the need to water solubilise the hydrophobic fullerene cages precedes an overview of fullerene-based diagnostic and therapeutic technologies. A final moment is spent on toxicity studies of fullerenes. The concluding remarks emphasise the positive effects of incorporating fullerenes into biomedical technologies, while looking at how these are perceived by the general public. A case is made for fullerenes being the optimal choice as standard bearers in the advance of nanomaterials into the medical field.

This is the winning review of the 2016 Materials Literature Review Prize of the Institute of Materials, Minerals and Mining, run by the Editorial Board of MST. Sponsorship of the prize by TWI Ltd is gratefully acknowledged.

Keywords

Fullerenes Water solubility Functionalisation Nanomedicine

Fullerenes

Why so interesting?

The fullerenes constitute a distinct allotrope in the family of carbon nanomaterials. Their unique cage-like structure and electron-deficient nature lead to fascinating properties which have made them a promising focus of research in an array of fields. The most abundant fullerene, C₆₀, has a van der Waals diameter of 10.18 Å,¹ positioning it well within the realm of nanotechnology. The origin of the fullerenes’ key properties and rich chemistry lies in the unique hybridisation of the strained carbon–carbon bonds; while the carbon atoms in graphene and carbon nanotubes (CNTs) are sp²-hybridised to give hexagonal networks, and the tetrahedral network of diamond is sp³-hybridised, the fullerenes are made up of a network of both hexagons (1,3,5-cyclohexatriene¹) and pentagons ([5]radialene), as shown in Fig. 1, leading to an average hybridisation of sp^2.278.³ The presence of pentagonal rings introduces a significant amount of strain into the network,² leading to a rehybridised three-dimensional structure with asymmetric π orbitals and thus three crucial properties.⁴ First, the fullerenes are excellent electron acceptors, with C₆₀ exhibiting six reversible reductions. ⁵ Second, the exterior of the cages can be decorated using a vast range of chemical reactions. Finally, the relative inertness of the interior of the cages facilitates the capture and isolation of ionic, atomic and even small molecular species. Considerations of both topology and orbital rehybridisation give the fullerenes their unique chemical properties.

1,3,5-Cyclohexatriene and [5]radialene sub-units, as found in C₆₀ (double bonds are emitted for clarity)

Size differences

While the fullerenes are a distinct allotrope of carbon, there is considerable variation within the family: the cages can consist of different numbers of carbon atoms, leading to different shapes and sizes. This increases their versatility and gives researchers considerably greater freedom in tailoring the molecules’ properties. C₆₀ is the smallest stable fullerene which obeys the isolated pentagon rule (IPR) – its football-like truncated icosahedron structure (I_h symmetry point group) leads to every carbon atom environment being identical, as elegantly shown by the sole peak in the¹³C NMR spectrum (Fig. 2a). This is in contrast to the five peaks for C₇₀ (Figs. 2b and c). Higher fullerenes exist, with adherence to the IPR a necessity for stability. Bigger cages have an increased number of isomers. This variation leads to differences in shape and symmetry, and makes isomeric isolation difficult and costly.^{3
4}

¹³C nuclear magnetic resonance (NMR) spectra of C₆₀ a and C₇₀ b. Every carbon environment in C₆₀ is identical (all are equally strained in the spherical structure), while there are five environments in C₇₀, corresponding to each successive, increasingly strained ‘layer’ of carbon atoms away from the equatorial plane c. NMR spectra were taken in carbon disulphide (CS₂) on a Bruker AVIII 400MHz machine

These differences in size and shape have significant effects on both the optical properties (Fig. 3) and chemical behaviour of the fullerenes. Solubility decreases with increasing cage size.⁸ Fullerenes are generally soluble in aromatic hydrocarbons and halogenated solvents, as well as CS₂.^{9, 10} The final size effect regards the reactivities of the fullerenes. The primary driving force for addition reactions is the relief of strain in the cage structure and the ensuing return to local sp³ hybridisation. Thus, fullerenes generally exhibit reduced reactivity as the cage size increases; the departure from a curved, strained surface to a more planar, graphitic topology explains this.¹¹

The absorption spectra of the fullerenes change as the size of the conjugated system increases: with slight variations depending on solvent, solutions of C₆₀ are an intense purple colour a, C₇₀ red like wine b and C₈₄ a green-yellow. (All above solutions in toluene). Generally speaking, the gap between the highest occupied molecular orbital and the lowest unoccupied molecular orbital decreases with increasing cage size leading to optical absorptions of lower energy, i.e. longer wavelength⁷

Synthesis

The mechanism of fullerene formation still remains a mystery despite numerous attempts at explanation. ¹² That has not, however, precluded our ability to produce tens of tons of C₆₀ per year. ¹³ This process put forward by Murayama et al. for Frontier Carbon Corporation (FCC) gives a soluble product mixture of 60% C₆₀ and 25% C₇₀, while the remaining 15% are higher fullerenes up to C₉₆. These are soluble in the organic solvents used for fullerene separation and constitute only 20% of the solid mass retrieved from the reaction chamber; the remaining 80% is insoluble carbonaceous soot. This compares favourably to the first process to produce fullerenes on the gram scale, the standard Krätschmer–Huffman arc discharge, where the fullerene content was and the relative intensities of the fullerene species were similar.¹⁴ In this now-standard process, electrical discharge creates a plasma which evaporates graphite in a helium atmosphere. That pioneering work built upon the initial discovery of C₆₀ 5 years earlier where it was produced using a low-yield laser ablation method.¹⁵ While it is now evident that the production of C₆₀ and C₇₀ has been successfully scaled-up, thus significantly driving down their cost,⁴ access to large quantities of higher fullerenes still remains an issue. Even more pressing is the difficulty in scalably synthesising endohedral fullerenes, something of crucial importance to potential future medical technologies.

Both size and synthesis issues impact the processability of different fullerenes and, as will be seen, their derivatives. Practical considerations of solubility, reactivity and scalable production methods play a great role in determining whether a fullerene-based technology can feasibly go to market; this is of particular importance in the pharmaceutical industry and will be touched upon throughout this review.

Exohedral functionalisation

The number of different reactions which have been carried out on fullerenes is immense and barely a fraction of them can be covered in this review.⁵ A selection of four reactions which are particularly relevant to the development of water-soluble fullerene derivatives for biomedical applications will be highlighted herein. Each will be examined in more general terms, with specific examples appearing later. It should also be noted that, unless stated otherwise, all reactions in this section were done with C₆₀.

The first two reactions, amination and hydroxylation, are each simple additions of a small polar functional group to the fullerene cage. They both give reasonable water solubilities but suffer from a total lack of control of the precise number of functional groups which are added to the cage.⁶ This is a major drawback for their deployment as pharmaceutically relevant reactions as this industry requires stringent control over its chemical structures; each batch of product synthesised must be as pure as possible, not only with respect to reagent impurities.

The second two reactions – the Prato¹⁷ and Bingel¹⁸ reactions, named after their discoverers – are very popular fullerene reactions, lauded for their ability to introduce a vast array of complex functional groups to the fullerene derivative in simple, one-pot processes. For this reason, they have been employed in numerous application areas besides water solubilisation.¹⁶ They are such robust reaction protocols that they have also been applied to functionalise CNTs. ^19,20

Amination

One of the first reactions to be carried out with fullerenes was the direct amination of C₆₀. ²¹ Wudl et al. simply mixed C₆₀ in a series of neat aliphatic primary amines (n-propylamine, t-butylamine⁷ and dodecylamine) for 16–24 h, observing a colour change through blue/green to brown. Precise elucidation of the number of adducts in each reaction was not carried out, although an average of six adducts was calculated⁸ for the n-propylamine reaction. Elsewhere, reaction of C₆₀ and C₇₀ with neat, excess, shorter chain primary and secondary amines (methylamine and diethylamine) yielded products containing up to 14 amine groups, as shown by mass spectrometry.²² Amination is an important reaction as it can lead to water-soluble derivatives, as demonstrated by the reaction of C₆₀ with ethylenediamine.²¹ The reaction mechanism for amination of C₆₀ is described in Fig. 4; addition occurs across the [6,6] bond. Interestingly, a density functional theory-based study has shown that the addition of methylamine to the larger C₈₀ cage takes place across the [6,5] bond, with subsequent additions preferentially occurring at [6,5] bonds in pentagons adjacent to the previous attachment site.²⁴ This could have useful consequences for the control of addition reactions to larger fullerenes.

Amination mechanism of C₆₀. The first step is single-electron transfer (a fast process) to produce the C₆₀ anion radical which has a characteristic green colour.²³ Radical recombination gives a zwitterion which can be stabilised by proton transfer to give the final product (a slow process giving a brown solution)

Hydroxylation

The synthesis of polyhydroxylated fullerenes (interchangeably called PHFs, fullerenols and fullerols⁹) was first achieved by Chiang et al.²⁵ who mixed C₆₀ and C₇₀ in an aqueous solution of sulphuric acid and nitric acid (optimum temperatures of 85–115C). An average of 14–15 hydroxyl groups attached to each cage. The more common method of hydroxylation involves stirring a solution of fullerenes in basic conditions. An exceptionally quick reaction time (three minutes) can be achieved by addition of excess aqueous NaOH to a benzene solution of C₆₀ in the presence of a small amount of tetrabutylammonium hydroxide, which acts as a phase-transfer catalyst.²⁶ Other quaternary ammonium hydroxides were tested as catalysts with a markedly less pronounced effect; the reaction took over 96 h in the absence of any catalyst. The average number of hydroxyl groups was , greater than the product from the acidic conditions of Chiang et al., and this corresponded to an increased water solubility: the greater the number of hydrogen bond donors, the greater the water solubility.

Despite the lack of precise control on the number of addends, hydroxylation has proved a very popular method of water solubilisation for both empty-cage and endohedral fullerenes, and a wide range of synthetic routes exist. ^27,28

Prato reaction

This 1,3-dipolar cycloaddition of an azomethine ylide to a fullerene gives a stable pyrrolidinofullerene product in good yield. The ylide is a reactive intermediate produced in situ by the condensation of an α-amino acid with an aldehyde or ketone, followed by decarboxylation (Fig. 5). The thermodynamically favoured product of this reaction involving C₆₀ has the pyrollidine ring attached across a [6,6] bond, with the kinetically favoured attachment being across the [6,5] bond. Cardona et al.³⁰ showed that these products were reversed (i.e. [6,6] adduct is kinetically favoured, [6,5] thermodynamically) in the case of endohedral metallofullerenes (EMFs) M₃N@C₈₀, leading to drastically different electrochemical behaviour.

Prato reaction mechanism (after Scarel²⁹). Initial attack of the aldehyde/ketone's polar carbonyl group by the nitrogen lone pair of the amino acid leads to the expulsion of water, before decarboxylation gives the reactive ylide intermediate

The beauty of the Prato reaction is its ability to introduce multiple functional groups to the fullerene moiety. Referring to Fig. 5, groups R₁, R₂ and R₃ can be tailored to the desired function. In particular, the possible variability of R₁ means the Prato reaction can proceed not only with primary but also secondary amino acids, thus expanding the reaction's applicability.

In contrast with the lack of control of the number of addends in the amination and hydroxylation reactions, good control can be achieved with the Prato reaction by tuning the stoichiometry of reagents and reaction time. Given that all [6,6] bonds on pristine C₆₀ are identical, all mono-adducts of the same addend are likewise identical. Significant regioisomerism and lack of control is, however, introduced on addition of a second addend to form a bis-adduct.³¹ The second addend has a choice of nine different [6,6] bonds at which to attach, as shown in Fig. 6, leading to a possible eight regioisomers (presuming the second addend is the same as the first). The difficulty in product purification which this regioisomerism introduces is compounded by the cis/trans isomerism present in pyrollidinofullerenes due to the chiral carbon atoms in the ring either side of the amino group (provided R₂, ). This could be of significance when looking at using fullerene derivatives in biomedical contexts as regioisomerism is known to have a significant effect on pharmaco-kinetics and -dynamics. ³² In a critical study – significant in deciding which route to take to well-defined fullerene multi-adducts – Lu et al. concluded that bis-addition using the Prato reaction cannot be as well controlled as with the Bingel reaction.³³ However, Zhou and Wilson³⁴ used a rigid tether between two azomethine ylides to controllably and selectively synthesise regioisomeric bis-adducts. This technique has found plenty of use with the Bingel reaction, but with the Prato reaction the chiral centres in the pyrrolidine rings introduce stereoisomeric complications.

Possible second addend addition sites (adapted after ³¹). There are three sites in the same hemisphere as the initial site of addition, giving rise to cis-regioisomers , and ; two equatorial sites, e' and e”; and four addition sites in the other hemisphere, giving trans-regioisomers , , and

Bingel reaction

Arguably the most popular reaction for exohedral functionalisation of fullerenes, this cyclopropanation involves the addition of an α-halo ester/ketone to the cage under strongly basic conditions (1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and NaH are most commonly used), yielding a methanofullerene.¹⁸ The mechanism of the classic reaction using a bromomalonate is given in Fig. 7. As with the Prato reaction, functional groups R₁ and R₂ can be specifically tailored to purpose; on the downside, the issue of regioisomerism in bis-adducts is also common. The popularity of the Bingel reaction, however, arises from versatile modifications of the original reaction, not least the ability to produce the halogenated intermediates in situ, which negates the need for their often time-consuming purification. Iodine³⁵ and tetrabromomethane (CBr₄)³⁶ have been effectively used for this purpose, with reaction yields of generally 30–60%. Also, unlike the Prato reaction which proceeds at , the Bingel reaction needs mild room temperature conditions.

Bingel reaction mechanism. Deprotonation by the strong base gives the nucleophilic malonate anion which then attacks the [6,6] bond. Bromine is then expelled as cyclisation is completed

Hirsch et al.³⁷ addressed the issue of regioisomerism arising from the Bingel reaction using a somewhat circuitous route to well-defined C₆₀ tris-adducts. After first synthesising the expected range of bis-adducts, the trans-3 (12.0% yield) and e (15.5% yield) regioisomers were isolated and further cyclopropanated. This yielded the tris-adducts seen in Fig. 8 in an impressive 40% yield. The tris-adduct from the trans-3 bis-adduct has all attachments at the trans-3 position (trans-3,trans-3,trans-3) and so symmetry; that from the e bis-adduct has all attachments at the equatorial positions (e,e,e) and so symmetry. A visible colour difference was also observed: the product being a more intense orange compared to the red of the product. These results indicate that functionalisation history affects the subsequent addition of other groups onto the fullerene cage and so can be used to control spatial functionalisation.

C₆₀ diethyl malonate tris-adducts. Addition at the trans-3 positions imparts symmetry and produces a red solution; at the equatorial positions, symmetry and an intense orange solution

Tethered moieties can also be used to direct functionalisation to specific points on the cage. Sigwalt et al.³⁸ successfully used tert-butyl(trialkoxy)silane tris-malonates to synthesise e,e,e tris-adducts (Fig. 9) in 8–26% yield. This method gives a notably increased yield in pure e,e,e tris-adduct final product compared to the functionalisation route via isolation of bis-adducts of Hirsch et al. above. Another attempt at e,e,e tris-adduct isolation, involving a protection–deprotection sequence based on the high-temperature () Diels–Alder reaction, achieved a meagre 4.2% yield in much harsher conditions.³⁹

tert-Butyl(trialkoxy)silane-tethered cyclopropanation e,e,e tris-adduct (2<n<4)

Fullerene derivatives with even more adducts might be desired for biomedical applications as a greater number of polar groups should give increased solubility. Hexakis-adducts of high symmetry with structurally complex malonates¹⁰ have been synthesised in good yield (40–68%) by Li et al.⁴⁰ who used a deceptively simple modification of the standard Bingel reaction. Instead of stoichiometric ratios specific for the desired product, they found that a 100-fold excess of the halogenating agent (in this case, CBr₄) preferentially yielded the hexakis adduct.

The introduction of carboxylic acid groups to the fullerene cage is an effective way of increasing the water solubility. However, as in the exemplary case of fullerene malonic acids,⁴¹ the carboxylic acid group is often introduced by base hydrolysis after the Bingel reaction has already taken place with a neutral diethyl malonate, as there would otherwise be unwanted acid base interaction. This represents a general issue of how to apply the Bingel reaction when incorporating acidic and base-labile functional groups. A work-around was discovered by Jin et al. who scrapped the need for a basic catalyst.⁴² Instead they used an amino acid (sarcosine) and DMSO to catalyse the reaction in chlorobenzene (PhCl) solution (Fig. 10), giving methanofullerene mono adducts in good yield (33–53%). A potential down side is that relatively large amounts (20 equivalents) of malonate were needed, so the synthesis of these must be scalable with that of the fullerene derivatives.

C₆₀ Bingel reaction in the presence of dimethyl sulphoxide (DMSO), with basic catalyst replaced by amino acid (adapted from Jin et al.⁴²). DMSO facilitates single-electron transfer from the amino acid to the fullerene to give the radical cation and radical anion respectively. The fullerene anion then attacks a brominated active methylene, expelling the bromine and forming a fullerenyl radical. Interaction between this and the amino acid radical cation from the first step then finalises cyclisation to give the desired methanofullerene

Endohedral functionalisation

The relatively inert interiors of the fullerenes render them able to capture atoms and atomic clusters within. The standard notation X@C_2n was introduced by Chai et al.⁴³ to denote endohedral fullerenes, where X is the incarcerated species and n specifies the cage size. Recently, a ‘molecular surgery’ approach, using a series of cage-opening and -closing chemical reactions, has led to the encapsulation of single molecules of hydrogen and water in C₆₀ to give H₂@C₆₀ and H₂O@C₆₀ (60–78% incorporation, respectively).⁴⁴ The focus of this section, however, will be on the EMFs, which are synthesised by more established procedures and have found extended use in research on fullerenes for medical applications.¹¹

Endohedral Metallofullerenes

This is a broad family of endohedral fullerenes where the cage plays host to either one (monometallic) or two (dimetallic) metal atoms or a cluster of metal atoms with another atom, often nitrogen. The presence of large metal atoms within the cage leads to differing reactivities and properties which can be exploited for numerous applications, including those in the biomedical realm.⁴⁶ In that field, the majority of literature covers the use of gadolinium-containing EMFs as contrast agents (CAs) in magnetic resonance imaging (MRI).

Synthesis. Much like C₆₀, the first EMFs were synthesised using expensive and low-yielding laser ablation.⁴⁷ Adaptations of the now-standard Krätschmer–Huffman arc discharge method have led to scaled-up synthesis of EMFs: composite graphite rods containing the desired metal oxide (most often lanthanide oxides) are used, however, yields are still generally less than 2% of the total carbonaceous material produced.^12,49 The major product of such a synthesis is monometallic fullerene, M@C₈₂, which has good solubility in common organic solvents and so can be separated from other products using HPLC. It should be noted that the first step of EMF isolation before HPLC separation is its extraction, using a standard Soxhlet method, from the carbon soot mixture by use of polar solvents such as dimethyl formamide (DMF). This is because the incarcerated metal atom does not sit centrally in the elongated cages of larger fullerene cages, giving the molecule an overall electric dipole moment. Kozlov et al.⁵⁰ optimised this standard process to produce Gd@C₈₂ of excellent purity (99%).

Stevenson et al.⁵¹ synthesised Sc₃N@C₈₀, the first trimetallic nitride template (TNT) EMF, in a marginally better 3–5% yield by introducing a small amount of nitrogen to the arc reactor. Their synthesis was vastly improved by Dunsch et al.⁵² whose ‘reactive gas atmosphere’ concept – the addition of ammonia into the reactor – gave EMFs as the majority fullerene product for the first time. The composition of the TNT EMFs can be generalised to X_xY_yM_3-x-yN@C₈₀, where X, Y and M are different metallic species. These species exist because the nitride clusters have been found to stabilise the high-symmetry -C₈₀ cage.

A further step towards commercial synthesis of TNT EMFs was achieved by Bezmelnitsyn et al.⁵³ whose novel approach to arc discharge, they estimate, has reduced the cost of lutetium-containing TNT EMF synthesis by 70–80%. A three-fold increase in yield was achieved by using a pyramidal three-phase AC arc discharge setup (cf. the standard two-electrode DC setup) along with a pure nitrogen atmosphere (negating the need for expensive helium) and metal oxide powder injection with solid graphite electrodes.

Exohedral functionalisation. The exohedral functionalisation of EMFs is even less trivial than that of empty-cage fullerenes.¹³ Entrapped metallic species transfer electrons to the carbon cage, with this excess electron density inhomogeneously distributed over the cage, and even extending out of it – a phenomenon dubbed ‘spin leakage’. ⁵⁵ This has profound effects on the chemistry of the EMFs.⁴⁶ Prato reactions have been carried out on La@C₈₂ to yield mono- and bis-adducts, with electron paramagnetic resonance measurements showing slight modification of the electronic structure upon mono-addition, and significant modification upon bis-addition.⁵⁶ Bingel cyclopropanation was used by Bolskar et al.⁵⁷ to isolate a derivative of the otherwise insoluble Gd@C₆₀. This is of value as the Gd@C₆₀ fraction of the arc discharge soot is more abundant than Gd@C₈₂ but could never be isolated due to its insolubility. A 15-fold excess of diethyl bromomalonate yielded primarily the decakis-adduct, Gd@C₆₀[C(COOCH₂CH₃)₂]₁₀, which was hydrolysed to the water-soluble Gd@C₆₀[C(COOH)₂]₁₀. This has been investigated as an MRI CA. Other Gd-EMF MRI CAs, which are examined later, have primarily been hydroxylated to achieve water solubility.

Fullerenes in medicine

Herein, a selection of water solubilisation methods are first covered in an attempt to discover which offer the most promise as potential platforms for medical tools. We then give a run-down of medical uses for which fullerenes have been investigated, offering a critical opinion as to which seem to show the most promise.

Water solubilisation

Pristine fullerenes are highly hydrophobic and so cannot be deployed in the body given that water is the primary constituent of blood into which medicines are delivered intravenously.¹⁴ Addition of hydrophilic, polar groups which are capable of hydrogen bonding with water molecules are the key to achieving water solubility; in turn, water solubility is the key to a longer retention time in the bloodstream due to decreased recognition as a foreign body by the immune system.

Covalent functionalisation is the surest way to producing fullerene-based systems viable for biomedical application as the structures of such molecules can be precisely defined (using X-ray crystallography) and their pharmaco-kinetic and -dynamic behaviour better understood and fine-tuned. This is in comparison with two other methods of water solubilisation:

Encapsulation in water-soluble hosts – Calixarenes are a good example of this type;⁵⁸

Supramolecular/covalent incorporation into water-soluble polymers – Giacalone et al.⁵⁹ give a good overview.

The major issues with these two methods are: the lack of definition of molecular structure in solution; inhomogeneity of samples;¹⁵ and unpredictable side effects from the water-solubilising component(s). Iwamoto and Yamakoshi⁶⁰ synthesised C₆₀–NVP (Fig. 11) with one of the highest water-solubilities (7.8 mM) of any fullerene derivative. However, being a polymeric system, it contains a spread of differently sized molecules ranging from 30 to 50 kDa, which is not specific enough to be scaled up to pharmaceutical scale.

C₆₀–N-vinylpyrrolidine (C₆₀–NVP) derivative

An easy route to water-soluble C₆₀ was first devised by Lamparth and Hirsch⁴¹, who recognised the need to isolate single regioisomers for investigation in biomedical studies. Thus, they took their previously synthesised and tris-adducts and hydrolysed them to the respective malonic acids by stirring in 20-fold excess of NaH for 3 h at . These products were very soluble, even in neutral water, and bis- and mono-adducts were also hydrolysed to confirm that water solubility did indeed increase with the number of carboxylic acid groups. These tris-adducts have been extensively studied for a variety of biomedical applications¹⁶ but there is a fear that the malonic acid groups are actually unstable under physiological conditions, leading to cytotoxic side products.⁶¹

Another successful water solubilisation via the Bingel reaction was achieved by Brettreich and Hirsch.⁶² Their dendro[60]fullerene mono-adduct (Fig. 12) gave the highest water solubility to date (12 mM). It signifies a different approach to the water solubilisation of fullerenes as it utilises the dendritic nature of the addend to introduce many polar groups and hydrophilicity, rather than adding the same small number of polar groups via multiple addends.

Dendro[60]fullerene mono-adduct

An early attempt to synthesise water-soluble fullerenes via the Prato reaction was not completely successful.⁶³ The introduction of two triethylene glycol chains off the pyrrolidine ring of the mono-adduct (34% yield) gave a poor upper limit to solubility of in a 9:1 water-DMSO binary solvent. Positively, however, this derivative showed promising anti-bacterial and anti-fungal activity. Aroua et al. used the Prato reaction to synthesise a versatile mono-adduct bis-carboxylic acid building block (Fig. 13) which was made water soluble () by subsequent PEGylation or reaction with the peptide sequence, GABA-GPLGVRGA.^17,64 Dynamic light scattering measurements confirmed a mono-modal distribution of aggregate particle diameter of . This small size and mono-modal distribution is required for biomedical applications so that the fullerene derivative can act efficiently and without unwanted aggregation effects.

C₆₀ mono-adduct bis-carboxylic acid building block for water-soluble derivatives

Hydroxylation is a very popular water-solubilisation method despite its lack of specificity. In their synthesis of Gd@C₈₂(OH)_x, Chen et al.⁶⁵ obtained a final product with a narrow distribution in the number of hydroxyl groups by selectively collecting only a cropped portion of HPLC fraction.

Diagnostics

Two non-invasive imaging techniques are investigated below, with readers directed elsewhere for a comprehensive discussion of such techniques.⁶⁶

Magnetic resonance imaging

The paramagnetic gadolinium(III) ion (Gd³⁺) is used in MRI CAs because its large magnetic moment and seven unpaired, isotropically distributed electrons (the highest number for any element) dramatically reduce the and relaxation times¹⁸ of any surrounding water protons, thus giving increased contrast in images. ^67,68 The percentage change in is greater than in and so the best visualisation is in so-called -weighted images.⁶⁹ In order for Gd³⁺ to enter the body, chelating agents are used to strongly bind the ion; several different chelating agents are currently available on the market and are used every day in hospitals across the world.⁷⁰ However, these chelating agents have limitations which it is hoped Gd-EMFs can alleviate. First, there is evidence that the highly toxic gadolinium ion can escape chelates in sufficient quantities to cause fatal damage to patients with renal failure. ^71,72 By capturing Gd³⁺ within a stable fullerene cage, there is no chance of escape and so that problem is negated. Second, as shown below, the relaxivity effects of Gd-EMFs can be over an order of magnitude greater than clinically available chelate-based CAs, meaning that lower doses can be administered for the same improvement in image contrast.⁷³ This might at first seem unexpected given that water molecules cannot directly interact with the gadolinium ion as it is shielded by the carbon cage, thus getting rid of all inner-sphere contributions to the relaxivity. Sitharaman et al.⁷⁴ found that Gd@C₆₀[C(COOH)₂]₁₀ and Gd@C₆₀(OH)_x form larger aggregates¹⁹ as the pH of the aqueous solution decreases. Thus they proposed that the large outer-sphere relaxivities observed are due to the slow tumbling of the aggregates formed.

Adding further evidence to this hypothesis, Zhang et al.⁷⁵ also observed a dependence of the relaxivities of the Gd₃N@C₈₀[DiPEG(OH)_x] on aggregate size. An optimum PEG chain weight of 350 Da gave aggregates of 95-,nm size and an of 237 mM⁻¹ s⁻¹ (2.4 T magnetic field), which compares very favourably to the r₁ values of low-molecular weight Gd³⁺-chelates which are typically 3–5 mM⁻¹ s⁻¹.⁷⁶ Laus et al.⁷⁷ note, however, that the formation of aggregates of Gd-EMFs can be disrupted, and so relaxivities reduced, by the addition of salts commonly found in the body (e.g. phosphates). Relaxivities were though still generally an order of magnitude greater than commercially available chelates.

This phenomenon of exceptional values is not limited to Gd-TNT EMFs, as Mikawa et al.⁷⁸ obtained an value of 81 mM⁻¹ s⁻¹ (1.0 T magnetic field) using Gd@C₈₂(OH)_x. Other examples of promising Gd-EMF MRI CAs have been synthesised^79,80 and Ghiassi et al.⁸¹ give a comprehensive outlook on the field.

Zhang et al.⁸² synthesised two novel water-soluble Gd-EMFs also containing scandium, which again showed improved relaxivities compared to commercial agents. Sc_xN@C₈₀(OH)_n (where ; ), respectively, gave values of 20.7 and 17.6 mM⁻¹ s⁻¹. This is an important result as Sc_xN@C₈₀ was synthesised in greater yields than both Gd@C₈₂ and Gd₃N@C₈₀, and was actually the third most abundant fraction from the arc discharge soot, after C₆₀ and C₇₀.

A remarkably high relaxivity of 368.7 mM⁻¹ s⁻¹ (1.5 T magnetic field²⁰) was achieved by combining pristine Gd@C₈₂ and water-soluble graphene oxide (GO).⁸³ π–π interactions between the GO and Gd-EMF are thought to facilitate electron transfer between the two and so help increase the observed relaxivity. While this nanohybrid is an exemplary system for achieving high relaxivities, it suffers from a lack of precise definition of what comprises the sample (e.g. the number of fullerenes per GO sheet).

Finally, Wang et al.⁸⁴ utilised C₆₀ as a central tethering moiety for the attachment of 4–5 Gd-DOTA²¹ chelates (Fig. 14). While admirable for exploiting C₆₀ as a three-dimensional chemical anchor and achieving an improved relaxivity of 49.7 mM⁻¹ s⁻¹, this novel derivative does not solve the issue of gadolinium escaping from its chelated state.

C₆₀-(Gd-DOTA)_n (n=4 or 5)

Deploying EMFs as MRI CAs is without doubt one of the most saturated spaces in biomedical fullerene research. Given the significant improvement in relaxivity which Gd-EMFs offer when compared with currently used Gd-chelates, and the lack of Gd-toxicity due to incarceration within the fullerene cage, it seems likely that this could be one of the first places we see fullerenes deployed as a biomedical tool. Improvements in synthesis routes, however, need to be achieved – specifically, higher-yielding arc discharge methods need to be scaled-up and controllable exohedral functionalisation must be achieved.

X-ray imaging

Wharton and Wilson⁸⁵ first developed a highly iodinated C₆₀ derivative (Fig. 15) for use as an X-ray imaging CA, mimicking the highly iodinated and highly water-soluble structure of commercially available Iohexol®. Using C₆₀ as a three-dimensional central anchor, Bingel cyclopropanation was initially used to add the highly iodinated addend before four further cyclopropanations introduced polar groups responsible for an impressive water-solubility of .

Highly iodinated and water-soluble C₆₀ derivative for X-ray imaging

In contrast²² to this exohedral introduction of multiple iodine atoms, Miyamoto et al.⁸⁶ investigated a range of fullerenol EMFs as X-ray CAs – it was hoped that these would abolish the need for iodinated agents, which can cause severe issues for patients with an allergy to iodine. The structures investigated – M@C₈₂(OH)₄₀ where M = Dy, Er, Gd, Eu or Lu₂ – unfortunately, however, did not produce contrast comparable to that of commercially available agents.

Therapeutics

Human immunodeficiency virus-1 (HIV-1) protease inhibitor

The first posited medical application of C₆₀ was as an inhibitor of human immunodeficiency virus-1 (HIV-1) protease, as the fullerene core is ideally suited to interact with the receptor site of the enzyme due to its hydrophobic surface and spherical shape.⁸⁷ By blocking the receptor site, the cleaving of proteins required for HIV replication and infection can no longer take place. In this initial work, Friedman et al. used water-soluble C₆₀ derivatised with bis(phenethyl-aminosuccinate) before suggesting, with the evidence of modelling, that direct amine additions to the cage could give better performance. A further modelling study by Tzoupis et al.⁸⁸ aimed to design fullerene derivative inhibitors by considering hydrogen-bond patterns, the regions of the receptor site most important for binding and contributions to the binding free energy. Recent work by Strom et al.⁸⁹ has shown that C₆₀-based amino acids can be further functionalised and their inhibition capability tuned by adding specially designed peptide sequences. Aside from inhibition of the protease enzyme, Tanimoto et al.⁹⁰ actually managed to degrade and thus render inactive HIV-1 protease by irradiating (365 nm) sugar-functionalised C₆₀ which had docked in the enzyme. This photodynamic effect is discussed further below.

Antioxidants

The role of oxidative stress – the unregulated and excessive proliferation of radicals, such as reactive oxygen species (ROS), within the body – in the pathogenesis of human disease cannot be overstated.⁹¹ While ROS, created by the partial reduction of oxygen,²³ are naturally produced by metabolic processes within the body and have even been found to play a key part in cellular signalling, deviation from homeostasis due to an increase in ROS levels²⁴ or a decrease in inherent antioxidant capability leads to problems.⁹³ Such problems include promotion of tumour metastasis, ⁹⁴ neurodegeneration⁹⁵ and other degenerative diseases associated with aging. ⁹⁶

Fullerenes have attracted much attention as potential antioxidant therapeutic agents due to their high capacity for radical quenching – they readily accept the lone electrons of radicals into their extended conjugated system. Beuerle et al.⁶¹ offer an excellent discussion on the efficacies of various fullerene derivatives in quenching a range of ROS. In groundbreaking work, Dugan et al.⁹⁷ showed that solutions of tris-malonic acids and eliminated all superoxide radicals generated in situ, and that the derivative in particular showed promising neuroprotective behaviour thanks to its antioxidant ability.⁹⁸ Further work from the same group showed that , when administered to non-human primates with Parkinson's disease, was responsible for improved motor function. ⁹⁹ These results and a myriad other studies looking at have established it as the poster-boy fullerene antioxidant, thus arguably propelling the field closer to market.⁶¹

Dendrofullerenes of first and second generation (see Figs. 16 and 12, respectively) were required in lower doses than both and for effective superoxide quenching, seemingly confirming that mono-adducts provide better antioxidant functionality thanks to a more intact conjugated system.¹⁰⁰

First generation water-soluble dendro[60]fullerene

Away from protection of the central nervous system and only superoxide quenching, Yin et al.¹⁰¹ found that PHFs offered better cytoprotection than bis-malonic acid, C₆₀(C(COOH)₂)₂. The protective effects of Gd@C₈₂(OH)₂₂ were found to be greater than its empty-cage C₆₀ analogue, C₆₀(OH)₂₂ and both were found to scavenge a range of physiologically relevant ROS. The radical scavening ability of fullerenols has even been used to treat lower back pain effectively.¹⁰²

Photodynamic therapy (PDT)

Photodynamic therapy (PDT) is lauded as an attractive cancer therapy for localised smaller lesions and carcinomas, as well as an aid during surgery of larger masses, thanks to its relative non-invasiveness, precise targeting and lack of long-term side effects.¹⁰³ It works by irradiating an intravenously administered photosensitising molecule at a particular wavelength, which excites it into its very short-lived (nanosecond scale) first excited singlet state, S₁. Non-radiative decay of this S₁ state gives the longer-lived (up to milli-second scale) triplet state, T₁, which is subsequently quenched.¹⁰⁴ In the case of molecular oxygen, quenching by energy transfer leads to the formation of a highly reactive and cytotoxic ROS: singlet oxygen ().¹⁰⁵ Thus, the effectiveness of PDT relies on the evolution of singlet oxygen in areas with a high density of cancerous cells.

Fullerene derivatives hold great promise as PDT photosensitisers due to their unprecedented efficiency of formation – for C₆₀ irradiated at 532 nm, this is unity.¹⁰⁶ There are, however, some drawbacks. The first is that C₆₀ absorbs well in the UV range and poorly at the red end of the electromagnetic spectrum; this matters as these are the wavelengths of the light sources typically used in PDT. The second potential drawback concerns the effect of multiple functionalisation of the fullerene cage. Hamano et al.¹⁰⁷ showed that increasing the number of addends decreased the efficiency of production. At the extreme end, a PHF exhibited zero photosensitisation. A final drawback is the solvent dependency of generation. Yamakoshi et al.¹⁰⁸ showed that, while is easily generated in non-polar solvents, and are the preferential products in polar solvents such as water and that these are the species responsible for DNA cleavage in physiological conditions, thus casting shadow over the precise mechanism(s) of PDT. Readers are directed to the review of Mroz et al.¹⁰⁹ for a fuller treatment of this topic.

Chemotherapy

PHFs are prevalent in the literature on cancer therapeutics, despite the specifics of their mechanism of action not being fully understood. Kang et al. and Pan et al. provided a detailed mechanistic insight into the action of Gd@C₈₂(OH)₂₂ on pancreatic tumour metastasis,²⁵ concluding that the amphiphilic nature of the PHF (hydrophobic cage carbons and hydrophilic hydroxyl groups) led to specific binding and enzymatic inhibition. ^110,111 Liu et al. recognised that, while sharing the same number of hydroxyl groups, Gd@C₈₂(OH)₂₂ outperformed C₆₀(OH)₂₂ in the inhibition of breast cancer metastasis. ¹¹² This is a good demonstration of the effect of the incarcerated species in EMFs on their reactivity, structure and subsequent function. Chen et al. found the antineoplastic activity of Gd@C₈₂(OH)₂₂ was considerably greater than that of commonly used cis-platin, thus adding weight to the claim for fullerenes to be used as chemotherapeutic agents.¹¹³

Theranostics

A distinct selling point of the fullerenes is their ability to combine multiple functionalities, thus making them viable theranostic²⁶ platforms.¹¹⁴ Theranostics offers an attractive route to personalised nanomedicines where exposure to treatment can be monitored and thus tailored for each patient individually.¹¹⁵,¹¹⁶

Photoacoustic imaging and photothermal therapy

This is a rather novel example of nanoparticles exhibiting useful theranostic qualities, with benefits of deeper tissue penetration and lower cost when compared with more traditional imaging modalities, e.g. MRI.¹¹⁷ Fullerenols (C₆₀(OH)_xNa_z) and carboxy-fullerene tris-adducts (C₆₀(C(COOH)₂)₃) were exposed to low-intensity near-IR laser irradiation (10 mJ cm⁻²) in both in vitro and in vivo²⁷ studies. A scanning ultrasound detection system detected a popping sound arising from the bursting of mesothelial lung carcinoma (A549) cells due to induced local heating of at least . Thus, not only were cancer cells destroyed, but the process could also be tracked by a cheap, non-invasive imaging technique using a laser power well within safety limits.

Brachytherapy, chemotherapy and dual-modal imaging

Shultz et al. synthesised a novel theranostic platform for MRI and brachytherapy²⁸ of brain tumours wherein Gd₃N@C₈₀ (water solubilised by both carboxyl and hydroxyl groups) was covalently linked to the DOTA chelating agent labelled with radioactive β-emitter,¹⁷⁷Lu.^29,118 Retention time in the tumour was good, allowing for good T₁-weighted imaging and effective delivery of brachytherapy. In a similar vain,¹⁷⁷Lu_xN@C₈₀, with the radiolabel within the fullerene cage, was developed by the same group.¹¹⁹ Fears of β decay destroying the fullerene cage were alleviated as there appeared to be little evidence of it after one half-life (6.7 days).

In the field of multi-modal imaging, Iezzi et al.¹²⁰ synthesised mixed-metal TNT EMFs, N@C₈₀ (M = Gd or Ho), where the lutetium atom provided X-ray imaging contrast on top of the MRI contrast provided by M. This is a promising result as these mixed-metal TNT EMFs were actually synthesised in higher yield than the mono TNT EMFs, e.g. Lu₃N@C₈₀. Another multi-modal imaging platform has been developed by Luo et al. for combined positron emission tomography (PET) and MRI.¹²¹ Exohedral addition of ¹²⁴I to hydroxylated Gd₃N@C₈₀ conferred the PET ability although, as with the X-ray CA of Wharton et al.,⁸⁵ iodine must be stably attached to the cage to avoid allergic reactions. A lack of iodine uptake in the thyroid gland seemed to suggest good stability of this molecule, giving it promise as a future dual-modal imaging tool.

Toxicity

The toxicity of fullerenes and their derivatives is a hotly debated topic amongst both researchers and regulatory bodies.^122,123 Particularly when dealing with synthetic routes to potential pharmaceutical products, low levels of genotoxic impurities will be introduced but must be minimised. ¹²⁴ As has been shown in the preceding sections, aggregation can have a great effect on the efficacy of administered nanoparticles³⁰ and its effects in physiological systems must be understood.¹²⁵

Kyzyma et al.¹²⁶ showed that aqueous solutions³¹ of C₆₀ had no toxic effects on Chinese-hamster V79 cells. However, cytotoxicity of C₆₀ in aqueous solution, mediated by singlet oxygen production, was seen in another study.¹²⁷ Most importantly, this study found that cytotoxicity is a sensitive function of the number of functional addends attached to the cage, with increased exohedral functionalisation decreasing cytotoxic effects by over seven orders of magnitude. This is in keeping with the results of Hamano et al.¹⁰⁷ discussed earlier.

Gao et al.¹²⁸ showed that C₆₀(OH)_24-26 presented no acute or chronic toxic effects in model organisms from four different kingdoms;³² on the contrary, there was evidence of increased growth and extended lifespan, which could have profound effects in environmental research areas such as biofuel production. With regard to cancer therapy, the antioxidant ability of C₆₀(OH)₂₄ has been shown to modulate cytotoxic effects of chemotherapeutic agent, doxorubicin (DOX), which induces ROS-mediated oxidative stress. ^129,130

Upon intravenous administration of future fullerene derivatives, the pharmaceutical must efficiently perform its function at the desired site, rather than just circulate throughout the body without specificity. Thus, a flagship targeted fullerene system was synthesised by Fan et al. who used a folic acid ligand to target tumour cells.¹³¹ Chemotherapy was delivered on-site by DOX as well as PDT thanks to the fullerene moiety. In an elegant twist, the intracellular release of DOX could be tracked as its fluorescence was quenched by C₆₀'s excellent affinity for electrons.

Concluding remarks

This review has taken a holistic approach to the deployment of fullerene derivatives in biomedical contexts. The unique electronic structure of a fullerene cage is shown to be the basis of its salient properties. A number of exohedral synthesis protocols have been critically examined, identifying the need for reproducible and scalable methods which yield well-defined addition patterns, in line with requirements of the pharmaceutical industry. Endohedral fullerenes remain a relatively exotic commodity; despite their numerous varieties and subsequent biomedical applications, even gram-scale quantities are hard to produce. Effective methods of water solubilisation have been critically evaluated, taking into account the need for well-defined addition patterns. The highest water-solubility to date has been achieved by a mono-functionalised dendrofullerene via the popular Bingel reaction, and this same reaction protocol proves robust for synthesising multi-adduct derivatives with well-defined structure. With this knowledge of product synthesis, applications of fullerene derivatives in diagnosis, therapy and theranostics were discussed. The literature on fullerenes as MRI CAs and antioxidants is vast and these appear to be very likely to make it to market soonest, given the marked improvements on technologies currently used in-clinic. Novel multifunctional theranostic platforms, however, demonstrate the fuller beauty and power of nanotechnology when applied to medicine. In spite of cytotoxicity arising from the efficient generation of singlet oxygen, fullerenes seem to exhibit little toxicity in their functionalised form.

As with all vying nanomaterials, if fullerenes are to reach the pharmaceutical market, and if fullerene-based nanomedicine¹³² is to find ubiquitous, daily application, then an understanding of the fundamental physical and chemical behaviour of these fascinating molecules necessarily precedes their technological exploitation.³³ Unlike other nanomaterials – such as CNTs,¹³⁷ graphene,¹³⁸ quantum dots (QDs) ¹³⁹ and superparamagnetic iron oxide nanoparticles (SPIONs)¹⁴⁰ – there is not an inherent heterogeneity of the base product. Each fullerene has a precisely defined structure in three-dimensional space. The importance of this cannot be overstated as, in drug discovery, it is the molecular structure which pharmaceutical companies patent. Thus, there is a significant distinction between fullerenes and graphene (whose sheets are of different size and termination), CNTs (whose length and chirality vary) and QDs and SPIONs (whose morphologies and topographies vary).

The benefits conferred through using fullerenes as medical tools could be immense, and it is the author's belief that they should and will soon be on the market. This will, however, require further interdisciplinary collaborations and a willing dialogue between academia and the pharmaceutical industry.

Footnotes

Acknowledgments

The author wishes to thank Prof. Kyriakos Porfyrakis for his support as DPhil supervisor, as well as the EPSRC for funding [EP/K030108/1].

Disclosure statement

No potential conflict of interest was reported by the author.

1

Differentiated from benzene due to the difference in bond lengths: the [6,6] bonds (double) between adjacent hexagons are 1.38 Å, while the [6,5] bonds (single) which form the borders between hexagons and pentagons are 1.45 Å.²

2

This strain accounts for approximately 80% of the heat of formation of C₆₀.³

3

It is worth mentioning at this point that the primary technique used to separate fullerenes from one another is high performance liquid chromatography (HPLC). Careful selection of the stationary phase and solvent system can lead to good separation of not only different sized cages, but also isomers containing the same number of atoms.⁶

4

C₆₀ can now be easily bought in large quantities at a price comparable to any standard laboratory chemical. MER Corporation of Arizona, USA sells 99+% pure batches of at $20 per gram. As a good example to see how the price and rarity increases with cage size, the same company sells C₇₀ of the same purity for $325 per gram, up to 25 g (Prices correct as of June 2016).

5

Readers are directed to the excellent monograph by Hirsch and Brettreich¹⁶ for a more complete overview of the library of fullerene reactions.

6

The ‘small polar functional group’ for amination here refers to the addition of methylamine.

7

Actually 1:3 t-butylamine:DMF.

8

Based on the ratios H:C and H:N.

9

The fact that there is no consensus on the name of this type of derivative should give an idea as to the lack of specificity associated with its structure and thus definition. This could conceivably cause regulatory issues and is a representative example of one of the stumbling blocks to fullerenes reaching the pharmaceutical market.

10

Compared to the simplicity of the prototypical diethyl malonate used in Bingel reactions.

11

Readers are directed to the review of Popov et al.⁴⁵ for a broader and more comprehensive outlook on the synthesis, properties and applications of endohedral fullerenes.

12

EMF yields are found to be dependent on many different parameters in the arc discharge reactor, with a strong dependence on the pressure of the He atmosphere.⁴⁸ Reactor size thus obviously has a major effect, as do rod size, distance between rods and current.

13

Researchers have attempted to make sense of this complex field in both theory⁵⁴ and experiment.

14

The favoured method of administering medicines as it is fastest and gives 100% bioavailability of the administered species.

15

This is particularly true when long-chain hydrophilic polymers are involved and control over the precise length of polymer chains is impossible. While more ethylene glycol units, for example, will lead to an increased solubility in polyethylene glycol (PEG)-based systems, the pharmaco-kinetic behaviour grows in complexity with increasing chain length due to increasing size and configurational entropy of the polymer chain. With a mixture of chain lengths in the sample, predicting behaviour within the body becomes even more difficult.

16

A full list would warrant further discussion beyond the scope of this review, so readers are directed to the extensive list offered by Beuerle et al.⁶¹

17

Each letter in this sequence corresponds to a different amino acid building block: G = glycine; A = alanine; B = asparagine or aspartic acid (ambiguous); P = proline; L = leucine; V = valine; R = arginine.

18

Thus increasing the relaxivities, respectively and .

19

Diameter increase from 30–90 to 600–1000 nm.

20

An even higher of 439.7 mM⁻¹ s⁻¹ was seen at 4.7 T.

21

DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)

22

Pun not intended.

23

There are many ROS but two of the most studied are the superoxide () and hydroxyl () radicals. Reduction of molecular oxygen yields the superoxide radical () which can dismutate to hydrogen peroxide (), which can then be fully reduced to water or partially reduced to the hydroxyl radical ().⁹²

24

This increase can be a result of endogenous generation (i.e. standard cellular activity) or exogenous sources (e.g. through smoking tobacco).

25

Through a combination of in vivo, in vitro and in silico observations.

26

Capable of both therapeutic and diagnostic functions.

27

However, given the lack of a targeting moiety on the fullerene cage, the in vivo study saw the fullerenols encapsulated within functionalised silica or chitosan nanoparticles.

28

Delivery of a radioactive source within the body so as to allow localised tumour targeting with minimal-radiation side effects cf. traditional radiotherapy using external X-ray sources.

29

¹⁷⁷Lu also emits γ radiation which could be detected by, for example, single-photon emission computed tomography (SPECT) for imaging purposes.

30

Although the size and length of an individual macromolecular fullerene might be well characterised, the average size and charge of many of them agglomerated together will vary from solvent to solvent, and could well lead to different toxic behaviour.

31

C₆₀ was first dissolved in N-methylpyrrolidine which also showed no cytotoxicity.

32

These were: algae (Pseudokirchneriella subcapitata); a plant (Arabidopsis thaliana); a fungus (Aspergillus niger); and an invertebrate (Ceriodaphnia dubia).

33

Science aside, the opinions of the public and key players in both policy and business (who may not have a specialist background) cannot be ignored.¹³³ Surveys have shown that the UK and US public view medical applications of nanotechnology in a less favourable light than energy applications. ¹³⁴ In one study, industry perceives fewer risks associated with nanotechnology than the public, and so does not enforce the regulations the public expects of such an industry.¹³⁵ This is likely to change in the near future as stricter definitions of a nanomaterial have been implemented by the European Union and include fullerenes within their scope.^122,136

ORCiD

I. Rašović

References

Taylor

and Walton

D. R. M.

: Nature, 1993, 363, (6431), 685–693.

Kadish

K. M.

and Ruoff

R. S.

: ‘Fullerenes: chemistry, physics, and technology’, 2000, New York, Wiley.

Haddon

R. C.

, Palmer

R. E.

, Kroto

H. W.

and Sermon

P. A.

: ‘The fullerenes: powerful carbon-based electron acceptors’, Philos. Trans. R. Soc. A: Math. Phys. Eng. Sci., 1993, 343, (1667), 53–62.

Fowler

P. W.

and Manolopoulos

D. E.

: ‘An Atlas of fullerenes’, ‘Dover books on chemistry’, 2006, New York, Dover Publications.

Xie

, Perez-Cordero

and Echegoyen

: ‘Electrochemical detection of C₆₀⁶- and C₇₀⁶-: enhanced stability of fullerides in solution’, J. Am. Chem. Soc., 1992, 114, (10), 3978–3980.

Gasper

M. P.

and Armstrong

D. W.

: ‘A comparative study of buckminsterfullerene and higher fullerene separations by HPLC’, J. Liq. Chromatogr., 1995, 18, (6), 1047–1076.

Diederich

, Ettl

, Rubin

, Whetten

R. L.

, Beck

, Alvarez

, Anz

, Sensharma

, Wudl

, Khemani

K. C.

and Koch

: ‘The Higher Fullerenes: Isolation and Characterization of C₇₆, C₈₄, C₉₀, C₉₄, and C₇₀O, an Oxide of D_5h-C₇₀’, Science, 1991, 252, (5005), 548–551.

Cataldo

and Da Ros

: ‘Medicinal chemistry and pharmacological potential of fullerenes and carbon nanotubes, ‘Carbon materials: chemistry and physics’, 2008, Berlin, Springer Science+Business Media.

Semenov

K. N.

, Charykov

N. A.

, Keskinov

V. A.

, Piartman

A. K.

, Blokhin

A. A.

and Kopyrin

A. A.

: ‘Solubility of light fullerenes in organic solvents’, J. Chem. Eng. Data, 2010, 55, (1), 13–36.

10.

Zhou

, Liu

, Jin

, Gu

, Wu

and Sun

: ‘Solubility of fullerene C₆₀ and C₇₀ in toluene, o-xylene and carbon disulfide at various temperatures’, Fullerene Sci. Technol., 1997, 5, (1), 285–290.

11.

Bingel

and Schiffer

: ‘Biscyclopropanation of C₇₀’, Liebigs Ann., 1995, 1551–1553.

12.

Goroff

N. S.

: ‘Mechanism of fullerene formation’, Acc. Chem. Res., 1996, 48824, (8), 77–83.

13.

Murayama

, Tomonoh

, Alford

J. M.

and Karpuk

M. E.

: ‘Fullerene production in tons and more: from science to industry’, Fuller. Nanotub. Car. N., 2005, 12, (February 2015), 1–9.

14.

Kratschmer

, Lamb

L. D.

, Fostiropoulos

and Huffman

D. R.

: ‘Solid C₆₀: a new form of carbon’, Nature, 1990, 347, 354–358.

15.

Kroto

H. W.

, Heath

J. R.

, O'Brien

S. C.

, Curl

R. F.

and Smalley

R. E.

: ‘C₆₀: buckminsterfullerene’, Nature, 1985, 318, (6042), 162–163.

16.

Hirsch

, Brettreich

and Wudl

: ‘Fullerenes: chemistry and reactions’, 2006, Weinheim, Wiley.

17.

Maggini

, Scorrano

and Prato

: ‘Addition of azomethine ylides to C₆₀: synthesis, characterization, and functionalization of fullerene pyrrolidines’, J. Am. Chem. Soc., 1993, 115, (21), 9798–9799.

18.

Bingel

: ‘Cyclopropanierung von fullerenen’, Chemische Berichte, 1993, 126, (8), 1957–1959.

19.

Georgakilas

, Kordatos

, Prato

, Guldi

D. M.

, Holzinger

and Hirsch

: ‘Organic functionalization of carbon nanotubes’, J. Am. Chem. Soc., 2002, 124, (5), 760–761.

20.

Coleman

K. S.

, Bailey

S. R.

, Fogden

and Green

M. L. H.

: ‘Functionalization of single-walled carbon nanotubes via the bingel reaction’, J. Am. Chem. Soc., 2003, 125, (29), 8722–8723.

21.

Wudl

, Hirsch

, Khemani

K. C.

, Suzuki

, Allemand

P-M.

, Koch

, Eckert

, Srdanov

and Webb

H. M.

: ‘Survey of chemical reactivity of C₆₀, electrophile, and dienopolarophile par excellence’ in ‘Synthesis, properties, and chemsitry of large carbon clusters’, (ed. G. S. Hammond and V. J. Kuck), chap. 11, ACS Symposium Series 481, 161–176; 1992, Washington, DC, American Chemical Society.

22.

Seshadri

, Govindaraj

, Nagarajan

, Pradeep

and Rao

C. N. R.

: ‘Addition of amines and halogens to fullerenes C₆₀ and C₇₀’, Tetrahedron Lett., 1992, 33, (15), 2069–2070.

23.

Brezova

, Stasko

, Rapta

, Domschke

, Bartl

and Dunsch

: ‘Fullerene anion formation by electron transfer from amino donor to photoexcited C₆₀. Electron paramagnetic resonance study’, J. Phys. Chem., 1995, 99, (44), 16234–16241.

24.

Amelines-Sarria

and Basiuk

V. A.

: ‘A DFT study of methylamine polyaddition to C₈₀ fullerene’, Superlattice Microst., 2009, 46, (1–2), 302–305.

25.

Chiang

L. Y.

, Swirczewski

J. W.

, Hsu

C. S.

, Chowdhury

S. K.

, Cameron

and Creegan

: ‘Multi-hydroxy additions onto C₆₀ fullerene molecules’, J. Chem. Soc. Chem. Commun., 1992, 1791–1793.

26.

, Takeuchi

, Ozawa

, Li

, Saigo

and Kitazawa

: ‘C₆₀ fullerol formation catalysed by quaternary ammonium hydroxides’, J. Chem. Soc. Chem. Commun., 1993, 1784–1785.

27.

Schneider

N. S.

, Darwish

A. D.

, Kroto

H. W.

, Taylor

and Walton

D. R. M.

: ‘Formation of fullerols via hydroboration of fullerene-C₆₀’, J. Chem. Soc. Chem. Commun., 1994, 463–464.

28.

Arrais

and Diana

: ‘Highly water soluble C₆₀ derivatives: a new synthesis’, Fullerene Nanotub. Carb. N., 2003, 11, (1), 35–46.

29.

Scarel

: ‘Fullerene-stoppered rotaxane : a multifunctional supramolecular material’, PhD thesis, Freiburg Institute of Advanced Studies, 2012.

30.

Cardona

C. M.

, Elliott

and Echegoyen

: ‘Unexpected chemical and electrochemical properties of M₃N@C₈₀ (M = Sc, Y, Er)’, J. Am. Chem. Soc., 2006, 128, (19), 6480–6485.

31.

Milic

and Prato

: ‘Fullerene unsymmetrical bis-adducts as models for novel peptidomimetics’, Eur. J. Org. Chem., 2010, 476–483.

32.

Chhabra

, Aseri

M. L.

and Padmanabhan

: ‘A review of drug isomerism and its significance’, Int. J. Appl. Basic Med. Res., 2013, 3, (1), 16–18.

33.

, Schuster

D. I.

and Wilson

S. R.

: ‘Preparation and characterization of six bis(N-methylpyrrolidine)-C₆₀ isomers: magnetic deshielding in isomeric bisadducts of C₆₀’, J. Organ. Chem., 1996, 61 (24), 4764–4768.

34.

Zhou

and Wilson

: ‘Tether-directed multiple functionalization of fullerene[60]’, Curr. Organ. Chem., 2005, 9, (8), 789–811.

35.

Nierengarten

J.-F.

and Nicoud

J.-F.

: ‘cyciopropanation of C₆₀ with malonic acid mono-esters’, Tetrahedron Lett., 1997, 38, (44), 7737–7740.

36.

Camps

and Hirsch

: ‘Efficient cyclopropanation of C₆₀ starting from malonates’, J. Chem. Soc. Perkin Trans. 1, 1997 (11), 1595–1596.

37.

Hirsch

, Lamparth

and Karfunkel

H. R.

: ‘Fullerene chemistry in three dimensions: isolation of seven regioisomeric bisadducts and chiral trisadducts of C₆₀ and Di(ethoxycarbonyl)methylene’, Angew. Chem. Int. Ed. Engl., 1994, 33, (4), 437–438.

38.

Sigwalt

, Schillinger

, Guerra

, Holler

, Berville

and Nierengarten

J-F.

: ‘An expeditious regioselective synthesis of [60]fullerene e,e,e tris-adduct building blocks’, Tetrahedron Lett., 2013, 54, (32), 4241–4244.

39.

Duarte-Ruiz

Á.

, Echegoyen

, Aya

and Gomez-Baquero

: J. Mex. Chem. Soc., 2009, 53, (3), 169–173.

40.

, Haque

S. A.

, Kitaygorodskiy

, Meziani

M. J.

, Torres-Castillo

and Sun

Y. P.

: ‘Alternatively modified Bingel reaction for efficient syntheses of C₆₀ hexakis-adducts’, Org. Lett., 2006, 8, (24), 5641–5643.

41.

Lamparth

and Hirsch

: ‘Water-soluble malonic acid derivatives of C₆₀ with a defined three-dimensional structure’, J. Chem. Soc. Chem. Commun., 1994, 1727–1728.

42.

Jin

, Shen

, Peng

, Zheng

and Chu

: ‘Efficient cyclopropanation of [60]fullerene starting from bromo-substituted active methylene compounds without using a basic catalyst’, Tetrahedron Lett., 2014, 55, (36), 5007–5010.

43.

Chai

, Cuo

, Jin

, Haufler

R. E.

, Chibante

L. P. F.

, Fure

, Wang

, Alford

J. M.

and Smalley

R. E.

: ‘Fullerenes wlth metals inside’, J. Phys. Chem., 1991, 95, (9), 7564–7568.

44.

Krachmalnicoff

, Levitt

M. H.

and Whitby

R. J.

: ‘An optimised scalable synthesis of H₂O@C₆₀ and a new synthesis of H₂@C₆₀’, Chem. Commun., 2014, 50, (86), 13037–13040.

45.

Popov

, Yang

and Dunsch

: Endohedral Fullerenes, Chem. Rev., 2013, 113, (8), 5989–6113.

46.

Dallas

, Rasovic

, Rogers

: in ‘Carbon nanomaterials sourcebook: graphene, fullerenes, nanotubes and nanodiamonds,’ (ed. Sattler

), chap. 10, 255–270; 2016, Boca Raton, Taylor & Francis.

47.

Heath

J. R.

, O'Brien

S. C.

, Zhang

, Liu

, Curl

R. F.

, Tittel

F. K.

and Smalley

R. E.

: ‘Lanthanum complexes of spheroidal carbon shells’, J. Am. Chem. Soc., 1985, 107, (25), 7779–7780.

48.

Saito

, Yokoyama

, Inakuma

and Shinohara

: ‘An ESR study of the formation of La@C₈₂ isomers in arc synthesis’, Chem. Phys. Lett., 1996, 250, (1), 80–84.

49.

Shinohara

: ‘Endohedral metallofullerenes’, Rep. Prog. Phys., 2000, 63, (6), 843–892.

50.

Kozlov

V. S.

, Suyasova

M. V.

and Lebedev

V. T.

: ‘Synthesis, extraction, and chromatographic purification of higher empty fullerenes and endohedral gadolinium metallofullerenes’, Russ. J. Appl. Chem., 2014, 87, (2), 121–127.

51.

Stevenson

, Rice

, Glass

, Harich

, Cromer

, Jordan

M. R.

, Craft

and Dorn

H. C.

: ‘Metallofullerenes in high yield and purity’, Nature, 1999, 80, 80–82.

52.

Dunsch

, Krause

, Noack

and Georgi

: ‘Endohedral nitride cluster fullerenes: formation and spectroscopic analysis’, J. Phys. Chem. Solids, 2004, 65, 309–315.

53.

Bezmelnitsyn

, Davis

and Zhou

: ‘Efficient synthesis of endohedral metallofullerenes in 3-phase arc discharge’, Fullerene Nanotub. Carb. N., 2014, 23, 612–617.

54.

Deng

and Popov

A. A.

: ‘Prato and bingel-hirsch cycloaddition to heptagon-containing LaSc₂N@Cs(hept)-C₈₀: importance of pentalene units’, Chem. Commun., 2015, 51, (26), 5637–5640.

55.

Koltover

V. K.

: ‘Spin-leakage of the fullerene shell of endometallofullerenes: EPR, ENDOR and NMR evidences’, Carbon, 2004, 42, 1179–1183.

56.

Cao

, Wakahara

, Maeda

, Han

, Akasaka

, Kato

, Kobayashi

and Nagase

: ‘Lanthanum endohedral metallofulleropyrrolidines: synthesis, isolation, and EPR characterization’, Chem. Eur. J., 2004, 10, (3), 716–720.

57.

Bolskar

, Benedetto

, Husebo

, Price

, Jackson

, Wallace

, Wilson

and Alford

: ‘First soluble M@C₆₀ derivatives provide enhanced access to metallofullerenes and permit in vivo evaluation of Gd@C₆₀ [C(COOH)₂]₁₀ as a MRI contrast agent’, J. Am. Chem. Soc., 2003, 125, (18), 5471–5478.

58.

Kunsági-Máté

, Szabó

, Bitter

, Nagy

and Kollar

: ‘Complex formation between water-soluble sulfonated calixarenes and C₆₀ fullerene’, Tetrahedron Lett., 2004, 45, (7), 1387–1390.

59.

Giacalone

, Martín

and Wudl

: in ‘Fullerene polymers,’ chap. 1, 1–14; 2009, Weinheim, Wiley-VCH.

60.

Iwamoto

and Yamakoshi

: ‘A highly water-soluble C₆₀-NVP copolymer: a potential material for photodynamic therapy’, Chem. Commun., 2006, 4805–4807.

61.

Beuerle

, Lebovitz

and Hirsch

: in ‘Medicinal chemistry and pharmacological potential of fullerenes and carbon nanotubes’, (ed. F. Cataldo & T. Da Ros), Vol. 1, chap. 3, 51–78; 2008, Berlin, Springer Science+Business Media.

62.

Brettreich

and Hirsch

: ‘A highly water-soluble dendro[60]-fullerene’, Tetrahedron Lett., 1998, 39, (18), 2731–2734.

63.

Da Ros

, Prato

, Novello

, Maggini

and Banfi

: ‘Easy access to water-soluble fullerene derivatives via 1,3-dipolar cycloadditions of azomethine ylides to C₆₀’, J. Organ. Chem., 1996, 61, (25), 9070–9072.

64.

Aroua

, Schweizer

W. B.

and Yamakoshi

: ‘C₆₀ pyrrolidine bis-carboxylic acid derivative as a versatile precursor for biocompatible fullerenes’, Organ. Lett., 2014, 16, 1688–1691.

65.

Chen

, Xing

, Wang

, Zhao

, Li

, Tang

, Jia

, Wang

, Sun

, Xing

, Yuan

, Chen

, Zhao

, Chai

and Fang

: ‘Multihydroxylated [Gd@C₈₂(OH)₂₂]n nanoparticles: antineoplastic activity of high efficiency and low toxicity’, Nano Lett., 2005, 82(10), 2050–2057.

66.

Kunjachan

, Ehling

, Storm

, Kiessling

and Lammers

: ‘Noninvasive imaging of nanomedicines and nanotheranostics: principles, progress, and prospects’, Chem. Rev., 2015, 115, (19), 10907–10937.

67.

Hagberg

and Scheffler

: ‘Effect of r₁ and r₂ relaxivity of gadolinium-based contrast agents on the T₁-weighted MR signal at increasing magnetic field strengths’, Contrast Media Mol. Imaging, 2013, 8, (6), 456–465.

68.

Amoroso

A. J.

and Pope

S. J. A.

: ‘Using lanthanide ions in molecular bioimaging’, Chem. Soc. Rev., 2015, 44, 4723–4742.

69.

Caravan

, Ellison

, McMurry

and Lauffer

: ‘Gadolinium-(III) chelates as MRI contrast agents: structure, dynamics, and applications’, Chem. Rev., 1999, 99, (9), 2293–2352.

70.

Caravan

: ‘Strategies for increasing the sensitivity of gadolinium based MRI contrast agents’, Chem. Soc. Rev., 2006, 35, (6), 512–523.

71.

Kuo

P. H.

, Kanal

, Abu-Alfa

A. K.

and Cowper

S. E.

: ‘Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis’, Radiology, 2007, 242, 647–649.

72.

Penfield

J. G.

and Reilly

R. F.

: ‘What nephrologists need to know about gadolinium’, Nat. Clin. Pract. Nephrol., 2007, 3, (12), 654–668.

73.

Hartman

and Wilson

: ‘Carbon nanostructures as a new high-performance platform for MR molecular imaging’ in Bio-applications of nanoparticles’, (ed. W. Chan), Vol. 620, chap. 6, 74–84; 2007, New York, Springer-Verlag.

74.

Sitharaman

, Bolskar

R. D.

, Rusakova

and Wilson

L. J.

: ‘Gd@C₆₀[C(COOH)₂]₁₀ and Gd@C₆₀(OH)_x : nanoscale aggregation studies of two metallofullerene MRI contrast agents in aqueous solution’, Nano Lett., 2004, 4, (12), 2373–2378.

75.

Zhang

, Shu

, Reid

, Owens

L. S.

, Cai

, Gibson

, Long

G. L.

, Corwin

F. D

, Chen

Z.-J.

, Fatouros

P. P.

and Dorn

H. C.

: ‘High relaxivity trimetallic nitride (Gd_3N) metallofullerene MRI contrast agents with optimized functionality’, Bioconjug Chem., 2010, 21, (4), 610–615.

76.

Yang

, Zhao

, Guo

, Li

, Tewary

and Xing

: ‘Nanoparticles, [Gd@C₈₂(OH)₂₂]n, induces dendritic cell maturation and activates Th1 immune responses’, ACS Nano, 2011, 4, (2), 1178–1186.

77.

Laus

, Sitharaman

, Tóth

É.

, Bolskar

R. D.

, Helm

, Asokan

, Wong

M. S.

, Wilson

L. J.

and Merbach

A. E.

: ‘Destroying gadofullerene aggregates by salt addition in aqueous solution of Gd@C₆₀(OH)x and Gd@C₆₀ [C(COOH₂)]₁₀’, J. Chem. Soc., 2005, 127, (26), 10–13.

78.

Mikawa

, Kato

, Okumura

, Narazaki

, Kanazawa

, Miwa

and Shinohara

: ‘Paramagnetic water-soluble metallofullerenes having the highest relaxivity for MRI contrast agents’, Bioconjugate Chem., 2001, 12, (4), 510–514.

79.

Shu

, Corwin

F. D.

, Zhang

, Chen

, Reid

J. E.

, Sun

, Xu

, Sim

J. H.

, Wang

, Fatouros

P. P.

, Alan

, Gibson

H. W.

and Dorn

H. C.

: ‘Facile preparation of a new gadofullerene-based magnetic resonance imaging contrast agent with high^1H relaxivity’, Bioconjug Chem., 2009, 20, (6), 1186–1193.

80.

Fatouros

P. P.

, Corwin

F. D.

, Chen

Z.-J.

, Broaddus

W. C.

, Tatum

J. L.

, Kettenmann

, Ge

, Gibson

H. W.

, Russ

J. L.

, Leonard

A. P.

, Duchamp

J. C.

and Dorn

H. C.

: ‘In vitro and in vivo imaging studies of a new endohedral metallofullerene nanoparticle’, Radiology, 2006, 240, (3), 756–764.

81.

Ghiassi

K. B.

, Olmstead

M. M.

and Balch

A. L.

: ‘Gadolinium-containing endohedral fullerenes: structures and function as magnetic resonance imaging (MRI) agents’, Dalton Trans., 2014, 43, 7346–7358.

82.

Zhang

E.-Y.

, Shu

C.-Y.

, Feng

and Wang

C.-R.

: ‘Preparation and characterization of two new water-soluble endohedral metallofullerenes as magnetic resonance imaging contrast agents’, J. Phys. Chem. B, 2007, 111, 14223–14226.

83.

Cui

, Li

, Huang

, Zhang

, Guo

, Chang

, Li

, Dong

, Sun

and Xing

: ‘Novel carbon nanohybrids as highly efficient magnetic resonance imaging contrast agents’, Nano Res., 2015, 8, (4), 1259–1268.

84.

Wang

, Zhu

, Tang

, Wu

, Zhou

, Sun

, Deng

S.-L.

, Ai

and Gao

: ‘A multiple gadolinium complex decorated fullerene as a highly sensitive T₁ contrast agent’, Chem. Commun., 2015, 51, (21), 4390–4393.

85.

Wharton

and Wilson

L. J.

: ‘Highly-iodinated fullerene as a contrast agent for X-ray imaging’, Bioorg. Med. Chem., 2002, 10, (11), 3545–3554.

86.

Miyamoto

, Okimoto

, Shinohara

and Shibamoto

: ‘Development of water-soluble metallofullerenes as x-ray contrast media’, Eur. Radiol., 2006, 16, (5), 1050–1053.

87.

Friedman

S. H.

, Decamp

D. L.

, Sijbesma

R. P.

, Srdanov

, Wudl

and Kenyon

G. L.

: ‘Inhibition of the HIV-1 protease by fullerene derivatives: model building studies and experimental verification’, J. Am. Chem. Soc., 1993, 115, (5), 6506–6509.

88.

Tzoupis

, Leonis

, Durdagi

, Mouchlis

, Mavromoustakos

and Papadopoulos

M. G.

: ‘Binding of novel fullerene inhibitors to HIV-1 protease: insight through molecular dynamics and molecular mechanics Poisson-Boltzmann surface area calculations’, J. Computer Aided Mol. Des., 2011, 25, (10), 959–976.

89.

Strom

T. A.

, Durdagi

, Ersoz

S. S.

, Salmas

R. E.

, Supuran

C. T.

and Barron

A. R.

: ‘Fullerene-based inhibitors of HIV-1 protease’, J. Peptide Sci., 2015, 21, (12), 862–870.

90.

Tanimoto

, Sakai

, Matsumura

, Takahashi

and Toshima

: ‘Target-selective photo-degradation of HIV-1 protease by a fullerene-sugar hybrid’, Chem. Commun., 2008 (44), 5767.

91.

Alfadda

A. A.

and Sallam

R. M.

: ‘Reactive oxygen species in health and disease’, J. Biomed. Biotechnol., 2012, 2012, 1–14.

92.

Turrens

J. F.

: ‘Mitochondrial formation of reactive oxygen species’, J. Physiol., 2003, 552, 335–344.

93.

Ray

P. D.

, Huang

B. W.

and Tsuji

: ‘Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling’, Cell. Signal., 2012, 24, (5), 981–990.

94.

Ishikawa

, Takenaga

, Akimoto

, Koshikawa

, Yamaguchi

, Imanishi

, Nakada

, Honma

and Hayashi

J.-I.

: ‘ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis’, Science, 2008, 320, (5876), 661–664.

95.

Shukla

, Mishra

S. K.

and Pant

H. C.

: ‘Oxidative Stress in Neurodegeneration’, Adv. Pharmacol. Sci., 2011 1–13.

96.

Ames

B. N.

, Shigenaga

M. K.

and Hagen

T. M.

: ‘Oxidants, antioxidants, and the degenerative diseases of aging’, Proc. Natl. Acad. Sci. U.S.A., 1993, 90, (17), 7915–7922.

97.

Dugan

L. L.

, Turetsky

D. M.

, Du

, Wheeler

, Almli

C. R.

, Shen

C. K.

, Luh

T. Y.

, Choi

D. W.

and Lin

T. S.

: ‘Carboxyfullerenes as neuroprotective agents’, Proc. Natl. Acad. Sci. U.S.A., 1997, 94, (17), 9434–9439.

98.

Dugan

L. L.

, Lovett

E. G.

, Quick

K. L.

, Lotharius

, Lin

T. T.

and O'Malley

K. L.

: ‘Fullerene-based antioxidants and neurodegenerative disorders’, Parkinsonism Relat. Disord., 2001, 7, (3), 243–246.

99.

Dugan

L. L.

, Tian

, Quick

K. L.

, Hardt

J. I.

, Karimi

, Brown

, Loftin

, Flores

, Moerlein

S. M.

, Polich

, Tabbal

S. D.

, Mink

J. W.

and Perlmutter

J. S.

: ‘Carboxyfullerene neuroprotection postinjury in Parkinsonian nonhuman primates’, Ann. Neurol., 2014, 76, (3), 393–402.

100.

Witte

, Beuerle

, Hartnagel

, Lebovitz

, Savouchkina

, Sali

, Guldi

, Chronakis

and Hirsch

: ‘Water solubility, antioxidant activity and cytochrome C binding of four families of exohedral adducts of C₆₀ and C₇₀’, Org. Biomol. Chem., 2007, 5, (22), 3599–3613.

101.

Yin

J. J.

, Lao

, Fu

P. P.

, Wamer

W. G.

, Zhao

, Wang

P. C.

, Qiu

, Sun

, Xing

, Dong

, Liang

X. J.

and Chen

: ‘The scavenging of reactive oxygen species and the potential for cell protection by functionalized fullerene materials’, Biomaterials, 2009, 30, (4), 611–621.

102.

Liu

, Jin

, Mahon

B. H.

, Chordia

M. D.

, Shen

F. H.

and Li

: ‘Novel treatment of neuroinflammation against low back pain by soluble fullerol nanoparticles’, Spine, 2013, 38, (17), 1443–1451.

103.

Stewart

, Baas

and Star

: ‘What does photodynamic therapy have to offer radiation oncologists (or their cancer patients)?’, Radiother. Oncol., 1998, 48, (3), 233–248.

104.

Wilkinson

, Helman

W. P.

and Ross

A. B.

: ‘Quantum yields for the photosensitized formation of the lowest electronically excited singlet state of molecular oxygen in solution’, J. Phys. Chem. Ref. Data, 1993, 22, (1993), 113.

105.

Wang

, Gao

, Zhou

and Selke

: ‘Nanomaterials and singlet oxygen photosensitizers: potential applications in photodynamic therapy’, J. Mater. Chem., 2004, 14, (4), 487.

106.

Arbogast

J. W.

, Darmanyan

A. P.

, Foote

C. S.

, Rubin

, Diederich

F. N.

, Alvarez

M. M.

, Anz

S. J.

and Whetten

R. L.

: ‘Photophysical properties of C₆₀’, J. Phys. Chem., 1991 (95), 11–12.

107.

Hamano

, Okuda

, Mashino

, Hirobe

, Arakane

, Ryu

, Mashiko

and Nagano

: ‘Singlet oxygen production from fullerene derivatives: effect of sequential functionalization of the fullerene core’, Chem. Commun., 1997, 21–22.

108.

Yamakoshi

, Umezawa

, Ryu

, Arakane

, Miyata

, Goda

, Masumizu

and Nagano

: ‘Active oxygen species generated from photoexcited fullerene (C₆₀) as potential medicines: O₂-• versus ¹O₂’, J. Am. Chem. Soc., 2003, 125, (42), 12803–12809.

109.

Mroz

, Tegos

G. P.

, Gali

, Wharton

, Sarna

and Hamblin

M. R.

: ‘Fullerenes as photosensitizers in photodynamic therapy’ in ‘Medicinal chemistry and pharmacological potential of fullerenes and carbon nanotubes’, (ed. F. Cataldo and T. Da Ros), Vol. 1, chap. 4, 79–106; 2008, Berlin, Springer Science+Business Media.

110.

Kang

S.-G.

, Zhou

, Yang

, Liu

, Sun

, Huynh

, Meng

, Zhao

, Xing

, Chen

, Zhao

and Zhou

: ‘Molecular mechanism of pancreatic tumor metastasis inhibition by Gd@C₈₂(OH)₂₂ and its implication for de novo design of nanomedicine’, Proc. Natl. Acad. Sci., 2012, 109, (38), 15431–15436.

111.

Pan

, Wang

, Kang

S.-G.

, Lu

, Yang

, Huynh

, Chen

, Zhou

, Guo

and Zhao

: ‘Gd-metallofullerenol nanomaterial suppresses pancreatic cancer metastasis by inhibiting the interaction of histone deacetylase 1 and metastasis-associated protein 1’, ACS Nano, 2015, 9, (7), 6826–6836.

112.

Liu

, Chen

, Qian

, Lu

, Sun

, Zhang

, Wang

, Gao

, Li

, Chen

, Tang

, Zhang

, Dong

, Bai

, Lobie

P. E.

, Wu

, Liu

, Zhang

, Zhao

, Wicha

M. S.

, Zhu

and Zhao

: ‘Gd-metallofullerenol nanomaterial as non-toxic breast cancer stem cell-specific inhibitor’, Nat. Commun., 2015, 6, 5988.

113.

Chen

, Xing

, Wang

, Zhao

, Li

, Tang

, Jia

, Wang

, Sun

, Xing

, Yuan

, Gao

, Meng

, Chen

, Zhao

, Chai

and Fang

: ‘Multihydroxylated [Gd@C₈₂(OH)₂₂]n nanoparticles: antineoplastic activity of high efficiency and low toxicity’, Nano Lett., 2005, 5, (10), 2050–2057.

114.

Chen

, Ma

, Liu

and Chen

: ‘Applications of functionalized fullerenes in tumor theranostics’, Theranostics, 2012, 2, (3), 238–250.

115.

Kelkar

S. S.

and Reineke

T. M.

: ‘Theranostics: combining imaging and therapy’, Bioconjug. Chem., 2011, 22, 1879–1903.

116.

Lim

E.-K.

, Kim

, Paik

, Haam

, Huh

Y.-M.

and Lee

: ‘Nanomaterials for theranostics: recent advances and future challenges’, Chem. Rev., 2015, 115, (1), 327–394.

117.

Krishna

, Singh

, Sharma

, Iwakuma

, Wang

, Zhang

, Knapik

, Jiang

, Grobmyer

S. R.

, Koopman

and Moudgil

: ‘Polyhydroxy fullerenes for non-invasive cancer imaging and therapy’, Small, 2010, 6, (20), 2236–2241.

118.

Shultz

M. D.

, Wilson

J. D.

, Fuller

C. E.

, Zhang

, Dorn

H. C.

and Fatouros

P. P.

: ‘Metallofullerene-based nanoplatform for brain tumor brachytherapy and longitudinal imaging in a murine orthotopic xenograft model’, Radiology, 2011, 261, (1), 136–143.

119.

Shultz

M. D.

, Duchamp

J. C.

, Wilson

J. D.

, Shu

C. Y.

, Ge

, Zhang

, Gibson

H. W.

, Fillmore

H. L.

, Hirsch

J. I.

, Dorn

H. C.

and Fatouros

P. P.

: ‘Encapsulation of a radiolabeled cluster inside a fullerene cage, ¹⁷⁷Lu_x Lu_(3-x)N@C₈₀: an interleukin-13-conjugated radiolabeled metallofullerene platform’, J. Am. Chem. Soc., 2010, 132, (14), 4980–4981.

120.

Iezzi

E. B.

, Duchamp

J. C.

, Fletcher

K. R.

, Glass

T. E.

and Dorn

H. C.

: ‘Lutetium-based trimetallic nitride endohedral metallofullerenes: new contrast agents’, Nano Lett., 2002, 2, (11), 1187–1190.

121.

Luo

, Wilson

J. D.

, Zhang

, Hirsch

J. I.

, Dorn

H. C.

, Fatouros

P. P.

and Shultz

M. D.

: ‘A dual PET/MR imaging nanoprobe: ¹²⁴I Labeled Gd₃N@C₈₀’, Appl. Sci., 2012, 2, (2), 465–478.

122.

Potocnik

: ‘On a code of conduct for responsible nanosciences and nanotechnologies research’, 2009, EUR 23906, ISBN 978-92-79-11605-6 Luxembourg, European Commission.

123.

Stone

, Hankin

, Aitken

, Aschberger

, Baun

, Christense

F. M.

, Fernandes

T. F.

, Hansen

S. F.

, Hartmann

N. B.

, Hutchison

G. R.

, Johnson

, Micheletti

, Read

, Ross

, Sokull-Kluettgen

, Stark

and Tran

: ‘ENRHES: Engineered nanoparticles: review of health and environmental safety’, 2010, Brussels, European Commission.

124.

Szekely

, Amores de Sousa

M. C.

, Gil

, Castelo Ferreira

and Heggie

: ‘Genotoxic impurities in pharmaceutical manufacturing: sources, regulations, and mitigation’, Chem. Rev., 2015, 115, (16), 8182–8229.

125.

Sharma

, Madhunapantula

S. V.

and Robertson

G. P.

: ‘Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems’, Expert Opin. Drug Metab. Toxicol., 2012, 8, 47–69.

126.

Kyzyma

E. A.

, Tomchuk

A. A.

, Bulavin

L. A.

, Petrenko

V. I.

, Almasy

, Korobov

M. V.

, Volkov

D. S.

, Mikheev

I. V.

, Koshlan

I. V.

, Koshlan

N. A.

, Blaha

, Avdeev

M. V.

and Aksenov

V. L.

: ‘Structure and toxicity of aqueous fullerene C₆₀ solutions’, J. Surf. Invest.: X-ray, Synchrotron Neutron Tech., 2015, 9, (1), 1–5.

127.

Sayes

C. M.

, Fortner

J. D.

, Guo

, Lyon

, Boyd

A. M.

, Ausman

K. D.

, Tao

Y. J.

, Sitharaman

, Wilson

L. J.

, Hughes

J. B.

, West

J. L.

and Colvin

V. L.

: ‘The differential cytotoxicity of water-soluble fullerenes’, Nano Lett., 2004, 4, (10), 1881–1887.

128.

Gao

, Wang

, Folta

K. M.

, Krishna

, Bai

, Indeglia

, Georgieva

, Nakamura

, Koopman

and Moudgil

: ‘Polyhydroxy fullerenes (fullerols or fullerenols): beneficial effects on growth and lifespan in diverse biological models’, PLoS ONE, 2011, 6, (5), 1–8.

129.

Djordjevic

and Bogdanovic

: ‘Fullerenol: a new nanopharmaceutic?’, Arch. Oncol., 2008, 16, (3–4), 42–45.

130.

Srdjenovic

, Milic-Torres

, Grujic

, Stankov

, Djordjevic

and Vasovic

: ‘Antioxidant properties of fullerenol C₆₀(OH)₂₄ in rat kidneys, testes, and lungs treated with doxorubicin’, Toxicol. Mech. Method, 2010, 20, (6), 298–305.

131.

Fan

, Fang

, Zeng

, Wang

and Wu

: ‘Water-dispersible fullerene aggregates as a targeted anticancer prodrug with both chemo- and photodynamic therapeutic actions’, Small, 2013, 9, 613–621.

132.

Jain

K. K.

: ‘The handbook of nanomedicine’, 2nd edn, 2012, New York, Springer.

133.

Besley

: ‘Current research on public perceptions of nanotechnology’, Emerg. Health Threats J., 2010, 3, e8.

134.

Pidgeon

, Harthorn

B. H.

, Bryant

and Rogers-Hayden

, ‘Deliberating the risks of nanotechnologies for energy and health applications in the United States and United Kingdom’, Nat. Nanotechnol., 2009, 4, (2), 95–98.

135.

Siegrist

, Wiek

, Helland

and Kastenholz

: ‘Risks and nanotechnology: the public is more concerned than experts and industry’, Nat. Nanotechnol., 2007, 2, (2), 67.

136.

Rauscher

, Sokull-Klüttgen

and Stamm

: ‘The European commission's recommendation on the definition of nanomaterial makes an impact’, Nanotoxicology, 2012, 7, 1–3.

137.

Baughman

R. H.

, Zakhidov

A. A.

and de Heer

W. A.

: ‘Carbon nanotubes on the route toward applications’, Science, 2002, 297, 787.

138.

Shen

, Zhang

, Liu

and Zhang

: ‘Biomedical applications of graphene’, Theranostics, 2012, 2, (3), 283–294.

139.

Medintz

I. L.

, Mattoussi

and Clapp

A. R.

: ‘Potential clinical applications of quantum dots’, Int. J. Nanomed., 2008, 3, (2), 151–167.

140.

Mahmoudi

, Sant

, Wang

, Laurent

and Sen

: ‘Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy’,Adv. Drug Deliv. Rev., 2011, 63, (1–2), 24–46.

Water-soluble fullerenes for medical applications

Abstract

Keywords

Fullerenes

Why so interesting?

Size differences

Synthesis

Exohedral functionalisation

Amination

Hydroxylation

Prato reaction

Bingel reaction

Endohedral functionalisation

Endohedral Metallofullerenes

Fullerenes in medicine

Water solubilisation

Diagnostics

Magnetic resonance imaging

X-ray imaging

Therapeutics

Human immunodeficiency virus-1 (HIV-1) protease inhibitor

Antioxidants

Photodynamic therapy (PDT)

Chemotherapy

Theranostics

Photoacoustic imaging and photothermal therapy

Brachytherapy, chemotherapy and dual-modal imaging

Toxicity

Concluding remarks

Footnotes

Acknowledgments

Disclosure statement

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

ORCiD

References